OPPIuM Technique and Myolysis With Diode Laser Dwls

NCT ID: NCT04748978

Last Updated: 2021-02-15

Basic Information

• Recruitment Status: UNKNOWN
• Clinical Phase: NA
• Total Enrollment: 35 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2020-09-01
• Study Completion Date: 2022-01-01

Brief Summary

PURPOSE OF THE STUDY The study aims to examine the feasibility and effectiveness of the OPPIuM technique combined with myolysis using the DWLS diode laser. In addition, to evaluate the reduction of myoma volume and the extent of uterine bleeding with myolysis to improve women's quality of life and avoid resectoscope hysteroscopy for a G2 MIOMA, which may lead to an increase in intraoperative surgical risks and long-term complications.

POPULATION 35 patients aged between 18 and 48 years with clinical and/or ultrasound diagnosis of uterine fibromatosis, belonging to the Endometriosis/Pelvic Chronic Pain Centre of the Complex Operating Unit of Gynecology of the University Polyclinic of Monserrato and other centers involved in the study. To be eligible for inclusion, patients with ultrasound and hysteroscopic diagnosis of a single submucosal myoma, partially intramural (G1 or G2) ≤ 3 cm, must present symptoms such as abnormal uterine bleeding and pelvic pain, for which surgical treatment was scheduled.

INCLUSION CRITERIA

• Women between 18 and 48 years old
• Diagnosis of symptomatic uterine fibromatosis (abnormal uterine bleeding and/or pelvic pain) with single fibroma ≤ 3 cm G1 or G2.

EXCLUSION CRITERIA Patients who cannot provide written informed consent or follow the procedures set out in the protocol.

• Patients with malignant neoplasms or serious systemic diseases
• Patients with multiple fibroids or single > 3 cm
• Asymptomatic patients
• Patients with other uterine or related diseases
• Patients seeking a pregnancy. INTERVENTION STRATEGY AND INSTRUMENTS

A total of 35 women will initially be included in the study, of which:

Patients will undergo the following assessments:

• Collection of physiological, pathological, and pharmacological anamnesis
• Collection of diagnostic tests (ultrasound) and staging of the underlying disease (uterine fibromatosis)
• Completion of the PBAC questionnaire
• Transvaginal ultrasound
• Office diagnostic hysteroscopy with OPPIuM and Myolysis
• Possible resectoscope hysteroscopy or laser myomectomy in narcosis.

Detailed Description

BACKGROUND Leiomyomas or uterine fibroids are benign lesions that can cause infertility, uterine bleeding (hypermenorrhea, metrorrhagia, and menometrorrhagia), resulting in anemia, disorders in urinary tract function and symptoms of abdominal pressure, chronic pelvic pain, and/or dysmenorrhea. Often doctors decide to remove the myoma or uterus to resolve the symptoms. Myomas or uterine fibroids occur in 25 to 44% of women during reproductive age. Myomas are more common in the fourth and fifth decade of life when their incidence can reach almost 70% in Caucasian women and over 80% in African origin women.

Submucosal fibroids are classified according to their development within the endometrial cavity in G0: intracavitary pedunculate fibroids G1 : fibromas whose intramural development is less than 50%. G2 : fibromas whose intramural development is greater than or equal to 50%. Resectoscope myomectomy for G2 myomas is a difficult procedure that should only be performed by surgeons experienced in hysteroscopy. In fact, resectoscope hysteroscopy is associated with a significant risk of complications that is proportional to the degree of intramural development of the myoma. Furthermore, the greater the myoma and its intramural development, the more likely the procedure will need to be divided into several surgical interventions.

As a result of these problems, several myolysis techniques have developed in which myomas are coagulated rather than removed using electrical energy or laser (thermomyolysis), liquid nitrogen (cryomyolysis), or recently even ultrasound.

Myolysis was performed for the first time by Mergui in France in 1987 using laser YAG to create holes in the myomas resulting in necrosis and narrowing. Later Leukens and Gallinat, in 1993, used bipolar needles from 1 to 3 cm to perform myolysis; their technique was similar to Mergui's.

In 2009 Bettocchi et al. evaluated the efficacy of a procedure to prepare submucosal fibromas with partially intramural development (G1 and G2) >1.5 cm in an outpatient setting (OPPIuM) to facilitate subsequent resectoscope hysteroscopic removal with the patient under general anesthesia.

It has been shown that if the pseudocapsule is removed, the myoma is pushed into the uterine cavity by myometrial contractions. The optimum technique, performed at the time of office hysteroscopy, consisted of incision of the endometrial mucosa and the pseudocapsule covering the myoma, using 5Fr scissors or Versapoint Twizzle bipolar electrode (Gynecare; Ethicon Inc., Somerville, NJ) until the precise identification of the contact surface between the myoma and the pseudocapsule itself. This procedure was intended to facilitate the intramural portion of the myoma protrusion into the cavity during subsequent menstrual cycles and facilitate subsequent resectoscope myomectomy under general anesthesia. Subsequently, in 2013 Haimovich et al. evaluated the feasibility of the same technique using diode laser.

To improve the results obtained in terms of controlled fibroma ablation, the investigators decided to combine the OPPIuM technique and myolysis with a new diode laser: DWLS. The combination of two wavelengths, 980 nm, and 1470 nm, gives a simultaneous absorption in H2O and hemoglobin with excellent hemostasis, cutting, and vaporization capacity, as previously demonstrated in laparoscopic and hysteroscopic surgery.

PURPOSE OF THE STUDY The study aims to examine the feasibility and effectiveness of the OPPIuM technique combined with myolysis using the DWLS diode laser. In addition, to evaluate the reduction of myoma volume and the extent of uterine bleeding with myolysis to improve women's quality of life and avoid resectoscope hysteroscopy for a G2 MIOMA, which may lead to an increase in intraoperative surgical risks and long-term complications.

EXPECTED BENEFITS Compared to the traditional technique (resectoscope hysteroscopic treatment) of G2 myomas, this approach could make the treatment simpler, faster, and in some cases unnecessary.

Compared to the OPPIuM technique with the bipolar electrode and subsequent resectoscope hysteroscopic treatment, the treatment with diode laser could:

1. obtaining the same result and in this case, a subsequent evaluation of comparison between the costs would be useful to evaluate the most suitable instrumentation from a health economics point of view;

2. could obtain a more important clinical result on the patient's symptomatology and volume reduction of myoma, thanks to the well-known properties of tissue vaporization of laser energy, which could avoid the traditional resectoscope hysteroscopic treatment in the operating room burdened with direct health costs and indirect and potential intra-operative or late complications.

INTERVENTION STRATEGY AND INSTRUMENTS The investigators plan to recruit 35 patients who are symptomatic but against hysterectomy and wish to keep the uterus with fibroids ≤ 3 G2. The subjects will be evaluated at the Endometriosis/Pelvic Pain Clinic of the Complex Operating Unit of Gynaecology of the University Hospital of Monserrato and in the other centers involved in the study. All patients will perform a transvaginal examination and ultrasound to provide accurate information on the submucosal myoma characteristics to be operated on and exclude other coexisting uterine or adjunct diseases.

A validated PBAC questionnaire will be filled in to assess the extent of uterine bleeding.

Before carrying out the in vivo test on the enrolled patients, an ex vivo test will be performed on myomas collected during a hysterectomy to evaluate which settings and wave powers are the best to achieve our goal for the myolysis step (the possible decrease in myoma volume).

An office hysteroscopy will be performed in the early proliferative menstrual phase. After a biopsy of the lesion and histological examination, the OPPIuM technique combined with myolysis with the DWLS diode laser using the Myolysis fiber will be performed.

After 1 or 2 menstrual cycles, a transvaginal ultrasound will be performed in the early proliferative phase to assess the volumetric reduction of myoma (following the myolysis). The PBAC questionnaire will be re-administered to assess the clinical response and the extent of uterine bleeding (following the combined technique), and one of the following 3 options will be decided with the patient:

1. do not re-intervene due to a reduction/disappearance of the lesion and/or resolution of the symptomatology

2. perform a second outpatient hysteroscopy to assess the protrusion in the endometrial cavity of the intramural portion of the myoma (following OPPIUM technique) and perform a possible outpatient laser myomectomy

3. program a laser/resettoscopic myomectomy in narcosis. The benefits that the patient can receive derive from the possibility of being able to avoid, thanks to a simple outpatient intervention, the intervention of resectoscope hysteroscopy in narcosis for MIOMA G2, which would lead to increase the intraoperative risks of hemorrhage, cervical trauma, gas embolism, uterine perforation, syndrome from intravasation and late complications such as postoperative intrauterine adhesions and uterine rupture during pregnancy.

The risks associated with the OPPIuM-MYOLYSIS outpatient procedure are, albeit to a very reduced extent compared to resectoscope hysteroscopy, bleeding, and uterine perforation.

With the OPPIuM-MYOLYS technique, complications related to cervical trauma would be avoided (because the cervical canal does not dilate, since the Bettocchi hysteroscope is 4 mm of a much smaller diameter than the resectoscope) and above all, the intravasation syndrome (because of the physiological saline solution at low pressure and for a short time).

Should a narcotic resectoscope hysteroscopy be scheduled due to the first OPPIuM-MYOLYS treatment's failure, the latter will allow surgeons to perform a resectoscope hysteroscopic myomectomy in less than 30 minutes on average, with reduced risks associated with prolonged anesthesia and intravasation syndrome. Furthermore, by favoring the expulsion of MIOMA G2 into the cavity (thus making it G0 or G1), it will be mainly intracavitary lesions, and surgeons will remove these lesions in a single surgical step without intraoperative complications such as uterine perforation, fluid overload, or intraoperative or postoperative bleeding.

POPULATION 35 patients aged between 18 and 48 years with clinical and/or ultrasound diagnosis of uterine fibromatosis, belonging to the Endometriosis/Pelvic Chronic Pain Centre of the Complex Operating Unit of Gynecology of the University Polyclinic of Monserrato and other centers involved in the study. To be eligible for inclusion, patients with ultrasound and hysteroscopic diagnosis of a single submucosal myoma, partially intramural (G1 or G2) ≤ 3 cm, must present symptoms such as abnormal uterine bleeding and pelvic pain, for which surgical treatment was scheduled.

STATISTICAL ANALYSIS The data will be tabulated on a specific database and analyzed using specific software. A descriptive output will be created, and the comparison between variables will be made through parametric and non-parametric tests with a level of significance of 95%. The IBM SPSS Statistics software will be used for statistical analysis.

Conditions

Uterine Fibroid; Myoma;Uterus

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

symptomatic uterine fibroids

patients aged between 18 and 48 years with clinical and/or ultrasound diagnosis of uterine fibromatosis

Group Type: EXPERIMENTAL

hysteroscopy

Intervention Type: PROCEDURE

OPPIum and Myolysis

Interventions

hysteroscopy

OPPIum and Myolysis

Intervention Type: PROCEDURE

Other Intervention Names

myolysis

Eligibility Criteria

Inclusion Criteria

• Women between 18 and 48 years old
• Diagnosis of symptomatic uterine fibromatosis (abnormal uterine bleeding, pelvic pain and/or infertility) with single fibroma ≤ 3 cm G1 or G2.

Exclusion Criteria

• Patients who are unable to provide written informed consent or to follow the procedures set out in the protocol.
• Patients with malignant neoplasms or serious systemic diseases
• Patients with multiple fibroids or single > 3 cm
• Asymptomatic patients
• Patients with other uterine or related diseases
• Patients seeking for a pregnancy.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 48 Years
• Eligible Sex: FEMALE
• Accepts Healthy Volunteers: Yes

Sponsors

University of Foggia

OTHER

Sponsor Role: collaborator

Azienda Ospedaliera Ordine Mauriziano di Torino

OTHER

Sponsor Role: collaborator

Civic Hospital, Italy

OTHER

Sponsor Role: collaborator

Clinical Hospital Center Rijeka

OTHER

Sponsor Role: collaborator

BelMedic Hospital, Beograd, Serbia

UNKNOWN

Sponsor Role: collaborator

University of Cagliari

OTHER

Sponsor Role: lead

Responsible Party

Stefano Angioni

Full Professor

Responsibility Role: PRINCIPAL_INVESTIGATOR

Locations

University of Cagliari,Obstetrics and Gynecological Department,

Monserrato, Cagliari, Italy

Site Status: RECRUITING

Countries

Italy

Central Contacts

Stefano Angioni, Prof

Role: CONTACT

sangioni@yahoo.it

07051093399

Facility Contacts

Stefano Angioni

Role: primary

sangioni@yahoo.it

07051093399

Maurizio N D'Alterio

Role: backup

mauridalte84@gmail.com

References

Stewart EA. Uterine fibroids. Lancet. 2001 Jan 27;357(9252):293-8. doi: 10.1016/S0140-6736(00)03622-9.

Reference Type: BACKGROUND

PMID: 11214143 (View on PubMed)

Zupi E, Sbracia M, Marconi D, Munro MG. Myolysis of uterine fibroids: is there a role? Clin Obstet Gynecol. 2006 Dec;49(4):821-33. doi: 10.1097/01.grf.0000211961.91616.78.

Reference Type: BACKGROUND

PMID: 17082676 (View on PubMed)

Bettocchi S, Di Spiezio Sardo A, Ceci O, Nappi L, Guida M, Greco E, Pinto L, Camporiale AL, Nappi C. A new hysteroscopic technique for the preparation of partially intramural myomas in office setting (OPPIuM technique): A pilot study. J Minim Invasive Gynecol. 2009 Nov-Dec;16(6):748-54. doi: 10.1016/j.jmig.2009.07.016.

Reference Type: BACKGROUND

PMID: 19896603 (View on PubMed)

Haimovich S, Mancebo G, Alameda F, Agramunt S, Sole-Sedeno JM, Hernandez JL, Carreras R. Feasibility of a new two-step procedure for office hysteroscopic resection of submucous myomas: results of a pilot study. Eur J Obstet Gynecol Reprod Biol. 2013 Jun;168(2):191-4. doi: 10.1016/j.ejogrb.2013.01.002. Epub 2013 Jan 31.

Reference Type: BACKGROUND

PMID: 23375904 (View on PubMed)

Angioni S, Pontis A, Sorrentino F, Nappi L. Bilateral salpingo-oophorectomy and adhesiolysis with single port access laparoscopy and use of diode laser in a BRCA carrier. Eur J Gynaecol Oncol. 2015;36(4):479-81.

Reference Type: BACKGROUND

PMID: 26390708 (View on PubMed)

Nappi L, Sorrentino F, Angioni S, Pontis A, Litta P, Greco P. Feasibility of hysteroscopic endometrial polypectomy using a new dual wavelengths laser system (DWLS): preliminary results of a pilot study. Arch Gynecol Obstet. 2017 Jan;295(1):3-7. doi: 10.1007/s00404-016-4232-5. Epub 2016 Nov 11.

Reference Type: BACKGROUND

PMID: 27834002 (View on PubMed)

Herman MC, Mak N, Geomini PM, Winkens B, Mol BW, Bongers MY; International Heavy Menstrual Bleeding IPD Meta-analysis Collaborative Group. Is the Pictorial Blood Loss Assessment Chart (PBAC) score associated with treatment outcome after endometrial ablation for heavy menstrual bleeding? A cohort study. BJOG. 2017 Jan;124(2):277-282. doi: 10.1111/1471-0528.14434.

Reference Type: BACKGROUND

PMID: 28012272 (View on PubMed)

Di Spiezio Sardo A, Mazzon I, Bramante S, Bettocchi S, Bifulco G, Guida M, Nappi C. Hysteroscopic myomectomy: a comprehensive review of surgical techniques. Hum Reprod Update. 2008 Mar-Apr;14(2):101-19. doi: 10.1093/humupd/dmm041. Epub 2007 Dec 6.

Reference Type: BACKGROUND

PMID: 18063608 (View on PubMed)

Other Identifiers

OPPIuM MYOLYSIS DWLS

Identifier Type: -

Identifier Source: org_study_id